Japan Reports Death Following COVID-19 Vaccine 日首例打疫苗後死亡 專家:與疫苗關聯性低 | 公視新聞網 PNN

Japan Reports Death Following COVID-19 Vaccine 日首例打疫苗後死亡 專家:與疫苗關聯性低

The first batch of COVID-19 vaccine has arrived in Taiwan. The CECC said healthcare and frontline workers will be given priority to receive the 117,000 doses. Meanwhile, Japan has reported the first death of a patient after getting a BNT vaccine. One expert in Taiwan says he believes the death has little association with the vaccine.


A patient in Japan has died of a subarachnoid hemorrhage after getting a COVID-19 vaccine. One expert in Taiwan says hemorrhagic strokes are chiefly caused by ruptured aneurysms and the death may be unrelated to the vaccine.
 
Subarachnoid hemorrhages are generally not associated with vascular obstructions. They are more often caused by vascular ruptures and therefore most likely unrelated to the vaccine.
 
Huang Li-min says vaccines produce a strong immune and inflammatory response usually in the form of pain and swelling around the injection site and in some cases headache, fever and muscle pain. As the government says vaccines will arrive in Taiwan any day now, Huang says the Tsai administration should establish an adverse reaction reporting system as soon as possible to prevent false information from spreading and people not wanting to get vaccinated.
 
The better way is for the government to find a credible organization to review side effect cases and determine if they were caused by the vaccine.
 
Huang also says Taiwan probably won't be able to achieve herd immunity until 2022.
 
 
 
日本傳出首例接種新冠輝瑞疫苗後,發生「蜘蛛膜下腔出血」死亡案例,是否和施打疫苗有關,仍有待釐清。對此,我國專家認為,「蜘蛛膜下腔出血」是一種急性出血性腦中風,主要原因是動脈瘤破裂所引起,有可能是個案本身就有疾病風險,和疫苗關聯性較低。
 
台灣感染症醫學會理事長 黃立民表示:「蜘蛛腦膜下出血,這跟血管阻塞,比較沒有關。它是一種有點像血管破裂那種出血,那這種很少在打疫苗之後引起的。」
 
黃立民表示,打疫苗會引發比較強烈的免疫發炎反應,常見包括注射部位疼痛、紅腫,少數有發燒、頭痛、肌肉痠痛等,較少發生出血性腦中風;由於台灣新冠疫苗即將開打,建議政府即早建立不良事件通報機制,第一時間和民眾溝通,否則很可能跟去年韓國接種流感疫苗死亡事件後,台灣出現緩打潮一樣。
 
台灣感染症醫學會理事長 黃立民表示:「比較好的作法,是政府要找一個有公信力的機構。要在第一時間就說,做一個初步的判斷。就是可能是,或者不確定,或者可能不是,讓民眾了解,專家初步判斷的結果。」
 
黃立民指出,台灣最快第一季、可望開始接種新冠疫苗,不過由於數量少,加上各種疫苗保護力、皆不同,要達到全人口、六成覆蓋率,恐怕得等到2022年才有機會達到群體免疫效果。
 

留言區